TxMD Transfusion Medicine Resources
TxMD™ Transfusion Medicine Program
TxMD is a collaborative partnership between Versiti and local hospitals. Through support from dedicated, specially trained personnel, our team identifies innovative transfusion medicine solutions to enhance patient safety and establish evidence-based blood administration practices. We strive to enhance the knowledge of all healthcare staff throughout our footprint who are involved with blood transfusion and related activities.
Two levels are offered:
- Support service to all Versiti blood services clients
- A TxMD customized program for contracted partners
The TxMD program offers onsite expertise, education, metrics and guidance to deliver sustained change in transfusion practice. Our focus for both service levels is to deliver appropriate, timely blood transfusion education materials and tools to improve operational efficiencies, reduce costs and advance quality of care.
Patient Blood Management
Patient blood management (PBM) is an evidence-based, multidisciplinary approach of various strategies and management during the continuum of care for patients who need transfusions. PBM’s primary goals are to improve patient safety and clinical outcomes by reducing the need for transfusion and appropriately managing a patient’s own blood.
In an increasingly complex healthcare environment, Versiti is committed to working with our hospital partners to support PBM efforts. Our goal is to ensure the right blood product to the right patient, at the right time and for the right reason.
Versiti Guidelines & Resources
- Versiti Blood Utilization Guidelines - Preface
- Versiti Blood Utilization Guidelines - Red Blood Cells
- Versiti Blood Utilization Guidelines - Plasma
- Versiti Blood Utilization Guidelines - Apheresis Platelets
- Versiti Blood Utilization Guidelines - Cryoprecipitated AHF
- Versiti Blood Utilization Guidelines - Modifications of Blood Components
- Versiti Blood Utilization Guidelines - Autologous and Directed Units
- Versiti Blood Utilization Guidelines - Factor Concentrates
- Versiti Blood Utilization Guidelines - Summary of Thresholds for Blood Component Transfusion
- Acceptable ABO/RhD Substitutions for Blood Products - ADULTS
- Acceptable ABO/RhD Substitutions for Blood Products - PEDIATRICS
- Example Guidelines for Transfusion and Anemia Management During Blood Product Shortages
- Managing Inventory During Blood Shortage
- Recommendations to Clinicians for Transfusion Practice During Blood Product Shortage
- Acute Transfusion Reactions: Signs, Symptoms, and Nursing Actions
- Delayed Transfusion Reactions: Signs, Symptoms, and Nursing Actions
- Tips for Transfusionists: Acceptable ABO/RhD Type for Commonly Transfused Blood Products
- Tips for Transfusionists: Checking Hemoglobin after Transfusion
- Tips for Transfusionists: Needle Gauge for Transfusion
- Tips for Transfusionists: Premedications Before a Blood Transfusion: Where's the Evidence?
- Tips for Transfusionists: Recommended Blood Adminstration Tubing
- Creating a Maximum Surgical Blood Ordering Schedule
- Guidelines for Use of Group O Neg RBCs
- O Negative RBC Tips for Optimizing Utilization
- O Negative Tips from Your Coach
- O Negative Tips from Your Coach Case Studies
- O Negative Tips from Coach Case Study Answers
- O Negative Hospital and Blood Center Roles in Utilization
- Apheresis Platelet Products Offered by Versiti: A Side by Side Comparison
- Pathogen Reduced Platelets
- Low Yield Platelets: Safety and Efficacy for Patient Care
- FAQs: Pathogen Reduced Apheresis Platelets & Use in Pediatric and Neonatal Patients
- FAQs: Apheresis Platelet Products Offered by Versiti to Meet the FDA Bacterial Mitigation Guidance
Questions Asked by Customers
ABO specific or compatible cryoprecipitate should be selected for pediatric or neonatal transfusions due to small blood volume of these patients. Single units of group AB cryoprecipitate are available from Versiti for neonates.
For adults (or patients >45 kg) any ABO group is acceptable. (See Acceptable ABO/RhD Substitutions for Blood Products – Adults.) Facilities may decide to limit number of units to avoid adverse effects from excessive volume of incompatible plasma.
Per CAP TRM.42100 (10-24-2022) and AABB BBTS 18.104.22.168 (33rd edition), when a hemolytic transfusion reaction occurs that is suspected to be related to an attribute of the donor or the blood component, the blood supplier must be notified.
Example: Suspected hemolysis due to passive ABO antibodies from ABO-nonspecific platelet transfusion (Group A recipient receives Group O or Group B apheresis platelet).
The irradiation indicator placed on the unit at the time of irradiation is an internal visual quality control check. The ISBT label is the permanent label for the product. The ISBT component code indicates the product has been irradiated and acceptable for patients who require this blood component modification.
Blood Products and Components
TxMD Transfusion Education Resources
Browse our information sheets and other materials about transfusion medicine and blood banking.